Considerations for drug development biomarker assays in the clinical laboratory

被引：1
|
作者：
Arnold, Mark E. [1 ]
Allinson, John L. [2 ]
Piccoli, Steven P. [3 ]
机构：
[1] Bioanalyt Solut Integrat, Westampton, NJ 08060 USA
[2] Immunologix Labs, Biomarker Lab, Tampa, FL 33634 USA
[3] Sun Pharm Adv Res Co Ltd, Clin Sci, Cranbury, NJ 08512 USA
来源：
BIOANALYSIS | 2023年 / 15卷 / 10期
关键词：
biomarkers; BMV; CAP; CLIA; clinical laboratory; context of use; drug development; regulations; US FDA; validation;
D O I：
10.4155/bio-2023-0101
中图分类号：
Q5 [生物化学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：533 / 536
页数：4
相关论文
共 50 条
  • [31] Development and validation of novel biomarker assays for osteoarthritis
    Ourradi, Khadija
    Xu, Yunhe
    de Seny, Dominique
    Kirwan, John
    Blom, Ashley
    Sharif, Mohammed
    PLOS ONE, 2017, 12 (07):
  • [32] Considerations in biomarker development for neurodevelopmental disorders
    McPartland, James C.
    CURRENT OPINION IN NEUROLOGY, 2016, 29 (02) : 118 - 122
  • [33] Considerations on development, validation, application, and quality control of immuno(metric) biomarker assays in clinical cancer research: An EORTC-NCI working group report
    Sweep, FCGJ
    Fritsche, HA
    Gion, M
    Klee, GG
    Schmitt, M
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2003, 23 (06) : 1715 - 1726
  • [34] ASSAYS OF SERUM LIPASE - ANALYTICAL AND CLINICAL CONSIDERATIONS
    LOTT, JA
    PATEL, ST
    SAWHNEY, AK
    KAZMIERCZAK, SC
    LOVE, JE
    CLINICAL CHEMISTRY, 1986, 32 (07) : 1290 - 1302
  • [35] Biomarker development in drug discovery and development
    Shinagawa, Akira
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2011, 115 : 54P - 54P
  • [36] Antiprogestin drug development: in vitro validation of a potential clinical biomarker.
    Gilles, Erard
    Caplier, Laura
    Valent, Alexander
    Serin, Guillaume
    Gompel, Anne
    Bosq, Jacques
    Zukiwski, Alexander
    CANCER RESEARCH, 2013, 73 (08)
  • [37] Pharmacogenetics in the clinical analysis laboratory: clinical practice, research, and drug development pipeline
    Miscio, Giuseppe
    Paroni, Giulia
    Bisceglia, Paola
    Gravina, Carolina
    Urbano, Maria
    Lozupone, Madia
    Piccininni, Carla
    Prisciandaro, Michele
    Ciavarella, Grazia
    Daniele, Antonio
    Bellomo, Antonello
    Panza, Francesco
    Di Mauro, Lazzaro
    Greco, Antonio
    Seripa, Davide
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2019, 15 (09) : 751 - 765
  • [38] Best Practices for Development and Validation of Enzymatic Activity Assays to Support Drug Development for Inborn Errors of Metabolism and Biomarker Assessment
    Azadeh, Mitra
    Good, Jeremy
    Gunsior, Michele
    Kulagina, Nadia
    Lu, Yanmei
    McNally, Jim
    Myler, Heather
    Ni, Yan G.
    Pelto, Ryan
    Quadrini, Karen J.
    Vrentas, Catherine
    Yang, Lin
    AAPS JOURNAL, 2024, 26 (05):
  • [39] Lipidomics in drug and biomarker development
    Wenk, Markus R.
    EXPERT OPINION ON DRUG DISCOVERY, 2006, 1 (07) : 723 - 736
  • [40] NASH: regulatory considerations for clinical drug development and US FDA approval
    Harvey, Brian E.
    ACTA PHARMACOLOGICA SINICA, 2022, 43 (05) : 1210 - 1214
12345